Henry Schein (HSIC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects that could drive the stock higher in the near term. The latest Zacks coverage argues that HSIC possesses solid growth attributes that could help it handily outperform the market, adding to recent analyses asking whether the stock is undervalued, highlighting it as a strong growth stock, and comparing it with Merit Medical (MMSI) to determine which offers the better value opportunity. All of these draw on Zacks’ Style Scores framework, which combines earnings-estimate and estimate-revision data with value…
Henry Schein Highlighted as Growth Stock in Zacks Analysis
Henry Schein (HSIC) possesses solid growth attributes, which could help it handily outperform the market, according to a Zacks analysis published on November 5, 2026.
The article, titled “Is Henry Schein (HSIC) a Solid Growth Stock? 3 Reasons to Think ‘Yes’,” frames the company’s growth characteristics as a potential source of market outperformance.
Coverage Context
The piece is part of a broader set of recent Zacks analyses on Henry Schein, which have included:
- An assessment of whether the stock is undervalued
- A look at its standing as a growth stock
- A comparison with Merit Medical (MMSI) to weigh which offers the better value opportunity
These analyses draw on Zacks’ Style Scores framework, which combines earnings-estimate and estimate-revision data with value metrics.
Key Points
- The analysis centers on Henry Schein’s growth attributes.
- Zacks states these attributes could help the company outperform the market.
- The article is categorized as general coverage on zacks.com.